Abstract
The use of controlled transdermal delivery of acyclovir (AC V) in the treatment of cutaneous herpes simplex virus type 1 infections in hairless mice was investigated. Using an in vivoanimal model (A. Gonsho, et al. Int. J. Pharm. 65:183–194 (1990)) made it possible to quantify both, the topical and the systemic antiviral efficacy of ACV transdermal patches as a function of the drug delivery rate of the patches. Drug delivery rates required to attain systemic efficacy were found to be higher than the rates required to attain the same magnitude of topical efficacy. The ACV concentrations in the basal cell layer of the epidermis for 50% topical efficacy and 50% systemic efficacy were estimated. The basal epidermis layer was considered to be the site of antiviral drug activity (skin target site). Systemic plasma levels were obtained from pharmacokinetic studies and were used to estimate the ACV concentration achieved systemically in the basal epidermis layer. A computational model for drug permeation across skin was employed to estimate the ACV concentration achieved topically in the basal epidermis layer. Equal topical and systemic efficacies were found to correspond to equal drug concentrations at the site of antiviral activity. The length of the effective diffusion pathway of drug molecules in the dermis prior to entering the blood circulation was assumed to be approximately equal to 1/20 of the anatomical dermis thickness because of dermis vascularization.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. Lieberman, T. W. Schafer, and P. E. Came. Chemotherapy of cutaneous herpesvirus infection of hairless mice. J. Invest. Dermatol. 60:203–206 (1973).
R. J. Klein, A. E. Friedman-Kien, and E. Brady. Herpes simplex virus skin infection in hairless mice: treatment with antiviral compounds. Antimicrob. Agents Chemother. 5:318–322 (1974).
M. Miyajima, T. Okano, S-W. Kim, and W. I. Higuchi. Preformulation of an ara-A transdermal delivery system: membrane fabrication and characterization. J. Controlled Release 5:179–186 (1987).
A. Gonsho, G. Imanidis, P. Vogt, E. R. Kern, H. Tsuge, M-H. Su, S-H. Choi, and W. I. Higuchi. Controlled (trans)dermal delivery of an antiviral agent (acyclovir) I: an in vivo animal model for efficacy evaluation in cutaneous HSV-1 infections. Int. J. Pharm. 65:183–194 (1990).
S. L. Spruance, and M. B. McKeough. Evaluation of antiviral treatments for recurrent herpes simplex labialis in the dorsal cutaneous guinea pig model. Antiviral Research 9:295–313 (1988).
J. C. Huff, G. G. Krueger, J. C. Overall, Jr., J. Copeland, and S. L. Spruance. The histopathologic evolution of recurrent herpes simplex labialis. J. Am. Acad. Dermatol. 5:550–557 (1981).
M. Gibaldi and D. Perrier. Pharmacokinetics, Second Edition, Marcel Dekker, Inc., New York and Basel, 1982, pp. 45–111.
F. Komada, G. Imanidis, M. Miyajima, T. Okano, M. J. Durrani, W. I. Higuchi, S-W. Kim, W.M. Shannon, and D. C. Baker. Design of 9-β-D-Arabinofuranosyladenine (Ara-A) transdermal delivery system for animal studies: regulation of drug concentration in vivo. J. Pharm. Sci. 80:935–941 (1991).
P. de Miranda, H. C. Krasny, D. A. Page, and G. B. Elion. Species differences in the disposition of acyclovir. Am. J. Med. 73:31–35 (1982).
C. D. Yu, W. I. Higuchi, N. F. H. Ho, J. L. Fox, and G. L. Flynn. Physical model evaluation of topical prodrug deliver—simultaneous transport and bioconversion of vidarabine-5′-valerate III: permeability differences of vidarabine and n-pentanol in components of hairless mouse skin. J. Pharm. Sci. 69:770–772 (1980).
K. S. Stenn. The skin. In L. Weiss (ed.), Histology, fifth edition, Elsevier Biomedical, New York, Amsterdam and Oxford, 1983, pp. 582–588.
P. H. Lee, M.-H. Su, E. R. Kern, and W. I. Higuchi. Novel animal model for evaluating topical effectiveness of antiviral agents: flux versus efficacy correlations in the acyclovir treatment of cutaneous HSV-1 infections in hairless mice. Pharm. Res. (in press).
W. B. Mahony, B. A. Domin, R. T. McConnell, and T. P. Zimmerman. Acyclovir transport into human erythrocytes. J. Biol. Chem. 263:9285–9291 (1988).
A. M. Al-Hasani, I. G. Barton, L. S. Al-Omer, G. R. Kinghorn, and C. W. Potter. Susceptibility of HSV strains from patients with genital herpes treated with various formulations of acyclovir. J. Antimicrob. Chemother. 18(Suppl.B):113–119 (1986).
C. McLaren, C. D. Sibrack, and D. W. Barry. Spectrum of sensitivity to acyclovir of herpes simplex virus clinical isolates. Acyclovir Symposium. Am. J. Med. 73:376–379 (1982).
D. F. Smee, N. L. Campbell, and T. R. Matthews. Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl) guanine, acyclovir and two 2′-fluoro-pyrimidine nucleosides, Antiviral Res. 5:259–267 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Imanidis, G., Song, Wq., Lee, P.H. et al. Estimation of Skin Target Site Acyclovir Concentrations Following Controlled (Trans)dermal Drug Delivery in Topical and Systemic Treatment of Cutaneous HSV-1 Infections in Hairless Mice. Pharm Res 11, 1035–1041 (1994). https://doi.org/10.1023/A:1018995606568
Issue Date:
DOI: https://doi.org/10.1023/A:1018995606568